Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

Brittany Schlater dominated the 2024 CPU Canadian National Championships and unofficially broke the Raw Deadlift IPF World ...

Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

R&D image Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, ...

Ade Omisakin has managed to demolish the U83KG IPF Raw Total World Record at the 2024 IPF Western European Powerlifting ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.